3 options
Cancer Policy: Pharmaceutical Safety / edited by June M. McKoy, Dennis P. West.
Holman Biotech Commons [v.107-v.109, v.111-v.128, v.130-136, v.139]
Mixed Availability
LIBRA v.1 (1981)-v.3 (1981), v.5 (1982)-v.36 (1987), v.38 (1988)-v.39 (1988), v.41 (1989)-v.55 (1991), v.57 (1991)-v.59 (1992), v.61 (1992)-v.73 (1994)
Mixed Availability
- Format:
- Book
- Series:
- Medicine (Springer-11650)
- Cancer treatment and research 0927-3042 ; 171.
- Cancer Treatment and Research, 0927-3042 ; 171
- Language:
- English
- Subjects (All):
- Oncology.
- Pharmacy.
- Drug Safety and Pharmacovigilance.
- Local Subjects:
- Oncology.
- Drug Safety and Pharmacovigilance.
- Physical Description:
- 1 online resource (V, 128 pages) : 1 illustrations.
- Edition:
- First edition 2019.
- Contained In:
- Springer eBooks
- Place of Publication:
- Cham : Springer International Publishing : Imprint: Springer, 2019.
- System Details:
- text file PDF
- Summary:
- Cancer Policy: Pharmaceutical Safety provides invaluable information on the interesting and compelling field of cancer drug safety. Identifying and understanding high-priority policy issues and key pharmacovigilance strategies is of paramount importance. In this volume, outstanding and original chapters provide an overview and synthesis of the latest thoughts and findings relating to drug safety in the cancer domain. Topics include natural language processing and pharmacovigilance of alternative cancer pharmaceuticals. The information presented in this volume will improve understanding of emerging strategies to identify adverse drug reactions and drug-drug interactions within the cancer setting and will highlight policies that have been instituted to improve cancer patient safety. In summary, Cancer Policy: Pharmaceutical Safety explores many of the important areas of pharmacovigilance research in oncology.
- Contents:
- Pharmacovigilance programs: Do they improve Cancer Drug Safety?
- Impact of Cost on the Safety of Cancer pharmaceuticals
- Assessing pharmaceutical safety in Geriatric Oncology
- Cancer co-Morbidity: Implications for Drug Safety
- Statistical aids to signal generation: Are they effective in Identifying Adverse Cancer Drug Reactions?
- Pharmacovigilance of alternative medications in the Cancer Setting
- Key elements in Adverse Drug Interaction Safety Signals: evaluation of individual case reports in oncology
- Biosimilars: Are they really safe?
- Natural Language processing: improving the identification and communication of Cancer Drug Safety
- The Drug Shortage Crisis in the United States: Impact on cancer pharmaceutical safety
- Anatomy of Risk Evaluation and Mitigation Strategies (REMS)
- Cancer Drug Toxicity: Moving from patient to Survivor.
- Other Format:
- Printed edition:
- ISBN:
- 978-3-319-43896-2
- 9783319438962
- Access Restriction:
- Restricted for use by site license.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.